1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Duchenne Muscular Dystrophy - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2019-2024) and Forecast (2025-2035)
4.4 Market Overview (2019-2024) and Forecast (2025-2035)
4.5 Competitive Intelligence
5 Duchenne Muscular Dystrophy - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Duchenne Muscular Dystrophy - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2025-2035)
7.2.3 Epidemiology by Age (2019-2035)
7.2.4 Epidemiology by Gender (2019-2035)
7.2.5 Diagnosed Cases (2019-2035)
7.2.6 Patient Pool/Treated Cases (2019-2035)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2025-2035)
7.3.3 Epidemiology by Age (2019-2035)
7.3.4 Epidemiology by Gender (2019-2035)
7.3.5 Diagnosed Cases (2019-2035)
7.3.6 Patient Pool/Treated Cases (2019-2035)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2025-2035)
7.4.3 Epidemiology by Age (2019-2035)
7.4.4 Epidemiology by Gender (2019-2035)
7.4.5 Diagnosed Cases (2019-2035)
7.4.6 Patient Pool/Treated Cases (2019-2035)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2025-2035)
7.5.3 Epidemiology by Age (2019-2035)
7.5.4 Epidemiology by Gender (2019-2035)
7.5.5 Diagnosed Cases (2019-2035)
7.5.6 Patient Pool/Treated Cases (2019-2035)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2025-2035)
7.6.3 Epidemiology by Age (2019-2035)
7.6.4 Epidemiology by Gender (2019-2035)
7.6.5 Diagnosed Cases (2019-2035)
7.6.6 Patient Pool/Treated Cases (2019-2035)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2025-2035)
7.7.3 Epidemiology by Age (2019-2035)
7.7.4 Epidemiology by Gender (2019-2035)
7.7.5 Diagnosed Cases (2019-2035)
7.7.6 Patient Pool/Treated Cases (2019-2035)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2025-2035)
7.8.3 Epidemiology by Age (2019-2035)
7.8.4 Epidemiology by Gender (2019-2035)
7.8.5 Diagnosed Cases (2019-2035)
7.8.6 Patient Pool/Treated Cases (2019-2035)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2025-2035)
7.9.3 Epidemiology by Age (2019-2035)
7.9.4 Epidemiology by Gender (2019-2035)
7.9.5 Diagnosed Cases (2019-2035)
7.9.6 Patient Pool/Treated Cases (2019-2035)
8 Duchenne Muscular Dystrophy Treatment - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Duchenne Muscular Dystrophy Treatment - Unmet Needs
10 Duchenne Muscular Dystrophy Treatment - Key Endpoints of Treatment
11 Duchenne Muscular Dystrophy Treatment - Marketed Products
11.1 List of Duchenne Muscular Dystrophy Treatment - Marketed Drugs Across the Top 7 Markets
11.1.1 Duvyzat (givinostat) - Italfarmaco
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
11.1.2 Elevidys (delandistrogene moxeparvovec-rokl) - Sarepta Therapeutics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Clinical Trial Results
11.1.2.4 Safety and Efficacy
11.1.2.5 Regulatory Status
11.1.3 Emflaza (deflazacort) - Marathon Pharmaceuticals/PTC Therapeutics
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Clinical Trial Results
11.1.3.4 Safety and Efficacy
11.1.3.5 Regulatory Status
11.1.4 PTC124 (Ataluren) - PTC Therapeutics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Clinical Trial Results
11.1.4.4 Safety and Efficacy
11.1.4.5 Regulatory Status
11.1.5 Eteplirsen (Exondys 51) - Sarepta Therapeutics
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Clinical Trial Results
11.1.5.4 Safety and Efficacy
11.1.5.5 Regulatory Status
Complete list to be provided in the final report.
12 Duchenne Muscular Dystrophy Treatment - Pipeline Products
12.1 List of Duchenne Muscular Dystrophy Treatment Pipeline Drugs Across the Top 7 Markets
12.1.1 RGX-202 - REGENXBIO
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Sevasemten (EDG-5506) - Edgewise Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Complete list to be provided in the final report.
13 Duchenne Muscular Dystrophy Treatment - Attribute Analysis of Key Marketed and Pipeline Drugs
14 Duchenne Muscular Dystrophy Treatment – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Duchenne Muscular Dystrophy Treatment Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Duchenne Muscular Dystrophy Treatment - Market Size
15.2.1.1 Market Size (2019-2024)
15.2.1.2 Market Forecast (2025-2035)
15.2.2 Duchenne Muscular Dystrophy Treatment - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2019-2024)
15.2.2.2 Market Forecast by Therapies (2025-2035)
15.3 Market Scenario - United States
15.3.1 Duchenne Muscular Dystrophy Treatment - Market Size
15.3.1.1 Market Size (2019-2024)
15.3.1.2 Market Forecast (2025-2035)
15.3.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
15.3.2.1 Market Size by Therapies (2019-2024)
15.3.2.2 Market Forecast by Therapies (2025-2035)
15.3.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Duchenne Muscular Dystrophy Treatment - Market Size
15.4.1.1 Market Size (2019-2024)
15.4.1.2 Market Forecast (2025-2035)
15.4.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
15.4.2.1 Market Size by Therapies (2019-2024)
15.4.2.2 Market Forecast by Therapies (2025-2035)
15.4.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Duchenne Muscular Dystrophy Treatment - Market Size
15.5.1.1 Market Size (2019-2024)
15.5.1.2 Market Forecast (2025-2035)
15.5.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
15.5.2.1 Market Size by Therapies (2019-2024)
15.5.2.2 Market Forecast by Therapies (2025-2035)
15.5.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview
15.6 Market Scenario – United Kingdom
15.6.1 Duchenne Muscular Dystrophy Treatment - Market Size
15.6.1.1 Market Size (2019-2024)
15.6.1.2 Market Forecast (2025-2035)
15.6.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
15.6.2.1 Market Size by Therapies (2019-2024)
15.6.2.2 Market Forecast by Therapies (2025-2035)
15.6.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview
15.7 Market Scenario – Italy
15.7.1 Duchenne Muscular Dystrophy Treatment - Market Size
15.7.1.1 Market Size (2019-2024)
15.7.1.2 Market Forecast (2025-2035)
15.7.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
15.7.2.1 Market Size by Therapies (2019-2024)
15.7.2.2 Market Forecast by Therapies (2025-2035)
15.7.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Duchenne Muscular Dystrophy Treatment - Market Size
15.8.1.1 Market Size (2019-2024)
15.8.1.2 Market Forecast (2025-2035)
15.8.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
15.8.2.1 Market Size by Therapies (2019-2024)
15.8.2.2 Market Forecast by Therapies (2025-2035)
15.8.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Duchenne Muscular Dystrophy Treatment - Market Size
15.9.1.1 Market Size (2019-2024)
15.9.1.2 Market Forecast (2025-2035)
15.9.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
15.9.2.1 Market Size by Therapies (2019-2024)
15.9.2.2 Market Forecast by Therapies (2025-2035)
15.9.3 Duchenne Muscular Dystrophy Treatment - Access and Reimbursement Overview
16 Duchenne Muscular Dystrophy Treatment - Recent Events and Inputs From Key Opinion Leaders
17 Duchenne Muscular Dystrophy Treatment Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Duchenne Muscular Dystrophy – Strategic Recommendations
19 Appendix